Cambrex Accelerates US and European Expansion Plans

Cambrex has announced significant progress in its US and European expansion strategy, reinforcing its position as a global contract development and manufacturing organisation. In the United States, the company has completed initial engineering studies for a new large scale active pharmaceutical ingredient facility in Iowa, part of a 120 million dollar investment. The expansion is expected to increase manufacturing capacity by around 20 percent and support complex chemistries, including highly potent compounds and peptide production.

In Europe, Cambrex is advancing a 30 million dollar upgrade at its Milan site in Italy. The project will enhance analytical development and research capabilities while modernising production infrastructure. The site will also benefit from additional land to support future growth and rising demand for outsourced pharmaceutical services.

These investments reflect growing industry demand for advanced drug substance manufacturing and a continued shift toward more localised supply chains. Cambrex aims to strengthen its ability to support pharmaceutical innovators with specialised technologies and scalable solutions across both regions.